Yankova et al. found treating tumours with STM2457, a METTL3 inhibitor, lead to reduced acute myeloid leukaemia (AML) growth and an increase in differentiation and apoptosis [79]. Other researchers also found that STM2457 can reverse small cell lung cancer chemoresistance by inducing mitophagy [80]. This evidence concerns the gene METTL3 and neoplasm.